Enanta Pharmaceuticals (9EP) Stock Statistics & Valuation Metrics

Enanta Pharmaceuticals has a market cap or net worth of CHF295.50M. The enterprise value is CHF416.67.

Enanta Pharmaceuticals has 29,125,402 shares outstanding. The number of shares has decreased by -2.65% in one year.

Enanta Pharmaceuticals’s return on equity (ROE) is -1.27 and return on invested capital (ROIC) is -31.44%.

The current PE Ratio of Enanta Pharmaceuticals is ―. Enanta Pharmaceuticals’s PEG ratio is 0.10.

In the last 12 months, Enanta Pharmaceuticals had revenue of 65.32M and earned -81.89M in profits. Earnings per share was -3.84.

In the last 12 months, operating cash flow was -35.32M and capital expenditures -1.62M, giving a free cash flow of -36.94M billion.

Enanta Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Enanta Pharmaceuticals upcoming earnings date is Nov 16, 2026, After Close (Confirmed).

Enanta Pharmaceuticals as a current ratio of 4.21, with Debt / Equity ratio of 55.07%

In the past 12 months, Enanta Pharmaceuticals has paid -1.66M in taxes.

Enanta Pharmaceuticals EV to EBITDA ratio is -5.99, with an EV/FCF ratio of -13.19.

Enanta Pharmaceuticals has CHF189.51M in cash and marketable securities with CHF55.66M in debt, giving a net cash position of CHF133.85M billion.

Gross margin is 98.15%, with operating margin of -130.65%, and net profit margin of -125.36%.

The average price target for Enanta Pharmaceuticals is CHF16.35, which is 11.43% higher than the current price. The consensus rating is Moderate Buy